Literature DB >> 25302362

A20--a bipartite ubiquitin editing enzyme with immunoregulatory potential.

Ingrid Wertz, Vishva Dixit.   

Abstract

Proper regulation of inflammation is essential for combating pathogen invasion and maintaining homeostasis. While hyporesponsive hosts succumb to infections, unchecked inflammatory reactions promote debilitating and fatal conditions including septic shock, autoimmune disease, atherosclerosis, graft rejection, and cancer. Pathogens, host immune cell ligands, and pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1-beta (IL1-beta), and Lipopolysaccharide (LPS) induce an array of inflammatory responses by activating a variety of cell types. Although much is known about how inflammatory responses are initiated and sustained, less is known about how inflammation is attenuated to maintain a homeostatic balance. In this chapter, we review the key role played by A20, also referred to as Tumor Necrosis Factor Inducible Protein 3 (TNFAIP3) in restoring cellular homeostasis through NF-kappaB inhibition, and discuss the molecular basis for its potent anti-inflammatory function as related to the ubiquitin editing and ubiquitin binding activities of A20.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25302362     DOI: 10.1007/978-1-4939-0398-6_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  14 in total

1.  The DNA methylation profile of activated human natural killer cells.

Authors:  John K Wiencke; Rondi Butler; George Hsuang; Melissa Eliot; Stephanie Kim; Manuel A Sepulveda; Derick Siegel; E Andres Houseman; Karl T Kelsey
Journal:  Epigenetics       Date:  2016-03-11       Impact factor: 4.528

2.  Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

Authors:  Arantza Azpilikueta; Elixabet Bolaños; Valerie Lang; Sara Labiano; Maria A Aznar; Iñaki Etxeberria; Alvaro Teijeira; Maria E Rodriguez-Ruiz; Jose L Perez-Gracia; Maria Jure-Kunkel; Juan M Zapata; Manuel S Rodriguez; Ignacio Melero
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

Review 3.  Coupling Conjugation and Deconjugation Activities to Achieve Cellular Ubiquitin Dynamics.

Authors:  Casey P Nielsen; Jason A MacGurn
Journal:  Trends Biochem Sci       Date:  2020-02-28       Impact factor: 13.807

4.  Glucocorticoid and TNF signaling converge at A20 (TNFAIP3) to repress airway smooth muscle cytokine expression.

Authors:  Sarah K Sasse; Mohammed O Altonsy; Vineela Kadiyala; Gaoyuan Cao; Reynold A Panettieri; Anthony N Gerber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-01       Impact factor: 5.464

Review 5.  The Proteasome and Its Network: Engineering for Adaptability.

Authors:  Daniel Finley; Miguel A Prado
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-01-02       Impact factor: 10.005

6.  Lys63-linked ubiquitin chain adopts multiple conformational states for specific target recognition.

Authors:  Zhu Liu; Zhou Gong; Wen-Xue Jiang; Ju Yang; Wen-Kai Zhu; Da-Chuan Guo; Wei-Ping Zhang; Mai-Li Liu; Chun Tang
Journal:  Elife       Date:  2015-06-19       Impact factor: 8.140

Review 7.  Post-translational control of RIPK3 and MLKL mediated necroptotic cell death.

Authors:  James M Murphy; James E Vince
Journal:  F1000Res       Date:  2015-11-19

8.  Multiple UBXN family members inhibit retrovirus and lentivirus production and canonical NFκΒ signaling by stabilizing IκBα.

Authors:  Yani Hu; Kaitlin O'Boyle; Jim Auer; Sagar Raju; Fuping You; Penghua Wang; Erol Fikrig; Richard E Sutton
Journal:  PLoS Pathog       Date:  2017-02-02       Impact factor: 6.823

Review 9.  NF-κB in inflammation and renal diseases.

Authors:  Haisong Zhang; Shao-Cong Sun
Journal:  Cell Biosci       Date:  2015-11-16       Impact factor: 7.133

10.  Interleukin-13 suppresses interleukin-10 via inhibiting A20 in peripheral B cells of patients with food allergy.

Authors:  Ming-Yang Li; Min Zhu; En-Qiang Linghu; Fan Feng; Bing Zhu; Cheng Wu; Ming-Zhou Guo
Journal:  Oncotarget       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.